Kiniksa Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $156,797 | $137,785 | $122,536 | $112,214 |
Gross Profit | 85,763 | 76,127 | 184,762 | 62,798 |
EBITDA | 20,160 | 13,617 | -18,899 | -9,259 |
EBIT | 20,160 | 13,272 | -19,299 | -9,658 |
Net Income | 17,832 | 8,539 | -8,888 | -12,693 |
Net Change In Cash | 156,797 | 137,785 | 122,536 | 112,214 |
Free Cash Flow | 27,925 | 22,225 | 18,577 | -2,236 |
Cash | 192,037 | 157,132 | 183,581 | 97,376 |
Basic Shares | 77,942 | 76,145 | 72,319 | 71,727 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $423,239 | $270,259 | $220,180 | $38,544 |
Gross Profit | 362,329 | 213,735 | 173,214 | 29,444 |
EBITDA | -45,616 | -22,855 | 9,773 | -154,281 |
EBIT | -45,616 | -25,196 | 5,553 | -156,636 |
Net Income | -43,193 | 14,084 | 183,363 | -157,924 |
Net Change In Cash | 423,239 | 270,259 | 220,180 | 38,544 |
Cost of Revenue | 245 | 8,222 | ||
Free Cash Flow | 25,412 | 13,171 | 5,702 | -146,713 |
Cash | 183,581 | 107,954 | 122,715 | 122,470 |
Basic Shares | 71,424 | 71,922 | 70,421 | 68,576 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.23 |
2025-03-31 | $0.11 |
2024-12-31 | -$0.12 |
